Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etirinotecan pegol - Nektar Therapeutics

Drug Profile

Etirinotecan pegol - Nektar Therapeutics

Alternative Names: Irinotecan - Nektar Therapeutics; NKTR-102; ONZEALD; PEG-Irinotecan; Pegylated irinotecan - Nektar Therapeutics

Latest Information Update: 17 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer Clovis Oncology [CEASED]; Mayo Clinic; Nektar Therapeutics; Roswell Park Cancer Institute; Stanford University School of Medicine; University of Pennsylvania Cancer Center
  • Class Alkaloids; Antineoplastics; Camptothecins; Heterocyclic compounds with 4 or more rings; Indolizines; Piperidines; Polyethylene glycols; Quinolines
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer; Cervical cancer; Colorectal cancer; Solid tumours
  • Discontinued Glioma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 01 Jun 2021 Discontinued - Phase-II for Colorectal cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Belgium, Germany, United Kingdom, Spain, India, USA, before June 2021 (IV)
  • 01 Jun 2021 Discontinued - Phase-II for Glioma (Monotherapy, Second-line therapy or greater) in USA before June 2021 (IV)
  • 01 Jun 2021 Discontinued - Phase-II for Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater) in USA before June 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top